Friedreich ataxia: clinical features and new developments.
Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR.
Neurodegener Dis Manag. 2022 Oct;12(5):267-283. doi: 10.2217/nmt-2022-0011. Epub 2022 Jun 29.
Friedreich's ataxia: clinical features, pathogenesis and management.
Cook A, Giunti P.
Br Med Bull. 2017 Dec 1;124(1):19-30. doi: 10.1093/bmb/ldx034.
Friedreich ataxia- pathogenesis and implications for therapies.
Delatycki MB, Bidichandani SI.
Neurobiol Dis. 2019 Dec;132:104606. doi: 10.1016/j.nbd.2019.104606. Epub 2019 Sep 5.
Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.
Bürk K, Schulz SR, Schulz JB.
J Neurochem. 2013 Aug;126 Suppl 1:118-24. doi: 10.1111/jnc.12318.
Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Profeta V, McIntyre K, Wells M, Park C, Lynch DR.
Expert Opin Investig Drugs. 2023 Jan;32(1):5-16. doi: 10.1080/13543784.2023.2173063. Epub 2023 Feb 8.
Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
Lynch DR, Perlman S, Schadt K.
Expert Rev Neurother. 2024 Mar;24(3):251-258. doi: 10.1080/14737175.2024.2310617. Epub 2024 Jan 30.
Friedreich's ataxia: new insights.
Krasilnikova MM, Humphries CL, Shinsky EM.
Emerg Top Life Sci. 2023 Dec 14;7(3):313-323. doi: 10.1042/ETLS20230017.
Friedreich ataxia.
Bodensteiner JB.
Semin Pediatr Neurol. 2014 Jun;21(2):72. doi: 10.1016/j.spen.2014.04.004. Epub 2014 Apr 2.
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
Pilotto F, Chellapandi DM, Puccio H.
Trends Mol Med. 2024 Feb;30(2):117-125. doi: 10.1016/j.molmed.2023.12.002. Epub 2024 Jan 24.
Friedreich ataxia.
Johnson WG.
Clin Neurosci. 1995;3(1):33-8.
